Former Nightstar Exec Gregory Robinson Joins Akouos as Chief Scientific Officer

Gregory Robinson has joined Akouos as chief scientific officer, the same position he held at gene therapy developer Nightstar Therapeutics. Nightstar was acquired by Biogen (NASDAQ: [[ticker:BIIB]]) earlier this year. Robinson’s experience also includes positions at Agilis Biotherapeutics, Shire, and Eyetech Pharmaceuticals. In other moves, Akouos co-founder Michael McKenna expanded his role to full-time chief medical officer after serving on a part-time basis since last year. Boston-based Akouos secured $50 million in financing last year to support development of a gene therapy to treat inherited forms of hearing loss.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.